Article

Second Booster Vaccine Dose for Older Adults and COVID-19 Mortality During the Omicron Surge

2022-03-25

Abstract excerpt

Background: The rapid emergence of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus-2 led to a global resurgence of coronavirus disease 2019 (Covid-19). On January 2nd, 2022, Israeli authorities approved a 4<sup>th</sup> Covid-19 vaccine dose (second-booster) for individuals aged 60 to 100 who received a first booster dose four or more months earlier. Evidence regarding the effecti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1e0d3df1-a0c6-5ac8-911e-cfd75a5c4738
DOI: 10.2139/ssrn.4066739

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Second Booster Vaccine Dose for Older Adults and COVID-19 Mortality During the Omicron SurgeDOI 10.2139/ssrn.4066739Read

Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years OldSemantic proximity Read

BNT162b2 vaccine booster dose protection: A nationwide study from IsraelSemantic proximity Read

Safety of the Fourth COVID-19 BNT162b2 mRNA (Second Booster) VaccineSemantic proximity Read

Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 MonthsSemantic proximity Read

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidenceSemantic proximity Read

Three doses of Sars-CoV-2 mRNA vaccine in older adults result in similar antibody responses but reduced cellular cytokine responses relative to younger adultsSemantic proximity Read

The Effectiveness of the First Dose of BNT162b2 Vaccine in Reducing SARS-CoV-2 Infection: Real-World EvidenceSemantic proximity Read

Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in BrazilSemantic proximity Read

Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccineSemantic proximity Read

Impact of accelerating booster vaccination amidst Omicron surge in the United StatesSemantic proximity Read

Effect of Vaccine Booster, Vaccine Type, and Hybrid Immunity on Humoral and Cellular Immunity Against SARS-CoV-2 Ancestral Strain and Omicron Variant Sublineages BA.2 and BA.5 Among Older Adults with Comorbidities: An Observational StudySemantic proximity Read

Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster doseSemantic proximity Read